vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Limbach Holdings, Inc. (LMB). Click either name above to swap in a different company.
Limbach Holdings, Inc. is the larger business by last-quarter revenue ($138.9M vs $86.8M, roughly 1.6× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 4.3%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
IOVA vs LMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $138.9M |
| Net Profit | — | $4.4M |
| Gross Margin | 67.4% | 22.4% |
| Operating Margin | -84.7% | 0.8% |
| Net Margin | — | 3.2% |
| Revenue YoY | 17.7% | 4.3% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $138.9M | ||
| Q4 25 | $86.8M | $186.9M | ||
| Q3 25 | $67.5M | $184.6M | ||
| Q2 25 | $60.0M | $142.2M | ||
| Q1 25 | $49.3M | $133.1M | ||
| Q4 24 | $73.7M | $143.7M | ||
| Q3 24 | $58.6M | $133.9M | ||
| Q2 24 | $31.1M | $122.2M |
| Q1 26 | — | $4.4M | ||
| Q4 25 | — | $12.3M | ||
| Q3 25 | $-91.3M | $8.8M | ||
| Q2 25 | $-111.7M | $7.8M | ||
| Q1 25 | $-116.2M | $10.2M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | $-83.5M | $7.5M | ||
| Q2 24 | $-97.1M | $6.0M |
| Q1 26 | — | 22.4% | ||
| Q4 25 | 67.4% | 25.7% | ||
| Q3 25 | 43.0% | 24.2% | ||
| Q2 25 | 5.5% | 28.0% | ||
| Q1 25 | -0.8% | 27.6% | ||
| Q4 24 | 68.7% | 30.3% | ||
| Q3 24 | 46.2% | 27.0% | ||
| Q2 24 | -0.8% | 27.4% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | -84.7% | 9.4% | ||
| Q3 25 | -140.7% | 7.2% | ||
| Q2 25 | -189.8% | 7.5% | ||
| Q1 25 | -245.8% | 5.9% | ||
| Q4 24 | -117.5% | 9.1% | ||
| Q3 24 | -152.1% | 8.1% | ||
| Q2 24 | -327.6% | 6.7% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | -135.3% | 4.8% | ||
| Q2 25 | -186.2% | 5.5% | ||
| Q1 25 | -235.5% | 7.7% | ||
| Q4 24 | — | 6.9% | ||
| Q3 24 | -142.7% | 5.6% | ||
| Q2 24 | -312.2% | 4.9% |
| Q1 26 | — | $0.36 | ||
| Q4 25 | — | $1.01 | ||
| Q3 25 | — | $0.73 | ||
| Q2 25 | $-0.33 | $0.64 | ||
| Q1 25 | $-0.36 | $0.85 | ||
| Q4 24 | $-0.24 | $0.81 | ||
| Q3 24 | $-0.28 | $0.62 | ||
| Q2 24 | $-0.34 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $15.8M |
| Total DebtLower is stronger | — | $56.6M |
| Stockholders' EquityBook value | $698.6M | $196.3M |
| Total Assets | $913.2M | $377.0M |
| Debt / EquityLower = less leverage | — | 0.29× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $15.8M | ||
| Q4 25 | $297.0M | $11.3M | ||
| Q3 25 | $300.8M | $9.8M | ||
| Q2 25 | $301.2M | $38.9M | ||
| Q1 25 | $359.7M | $38.1M | ||
| Q4 24 | $323.8M | $44.9M | ||
| Q3 24 | $397.5M | $51.2M | ||
| Q2 24 | $412.5M | $59.5M |
| Q1 26 | — | $56.6M | ||
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $56.3M | ||
| Q2 25 | — | $28.4M | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | — | $23.6M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $19.7M |
| Q1 26 | — | $196.3M | ||
| Q4 25 | $698.6M | $195.7M | ||
| Q3 25 | $702.3M | $181.6M | ||
| Q2 25 | $698.5M | $170.5M | ||
| Q1 25 | $767.9M | $161.1M | ||
| Q4 24 | $710.4M | $153.5M | ||
| Q3 24 | $773.5M | $142.2M | ||
| Q2 24 | $768.5M | $133.0M |
| Q1 26 | — | $377.0M | ||
| Q4 25 | $913.2M | $381.1M | ||
| Q3 25 | $904.9M | $409.1M | ||
| Q2 25 | $907.4M | $343.0M | ||
| Q1 25 | $966.7M | $336.4M | ||
| Q4 24 | $910.4M | $352.1M | ||
| Q3 24 | $991.1M | $324.4M | ||
| Q2 24 | $964.3M | $303.9M |
| Q1 26 | — | 0.29× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $28.1M | ||
| Q3 25 | $-78.7M | $13.3M | ||
| Q2 25 | $-67.4M | $2.0M | ||
| Q1 25 | $-103.7M | $2.2M | ||
| Q4 24 | $-73.3M | $19.3M | ||
| Q3 24 | $-59.0M | $4.9M | ||
| Q2 24 | $-98.4M | $16.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $27.9M | ||
| Q3 25 | $-89.5M | $12.8M | ||
| Q2 25 | $-74.9M | $1.2M | ||
| Q1 25 | $-109.9M | $11.0K | ||
| Q4 24 | $-77.5M | $18.0M | ||
| Q3 24 | $-61.3M | $4.6M | ||
| Q2 24 | $-98.9M | $13.2M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 14.9% | ||
| Q3 25 | -132.7% | 7.0% | ||
| Q2 25 | -124.9% | 0.8% | ||
| Q1 25 | -222.8% | 0.0% | ||
| Q4 24 | -105.1% | 12.5% | ||
| Q3 24 | -104.6% | 3.4% | ||
| Q2 24 | -317.9% | 10.8% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 16.1% | 0.3% | ||
| Q2 25 | 12.4% | 0.6% | ||
| Q1 25 | 12.6% | 1.7% | ||
| Q4 24 | 5.7% | 0.9% | ||
| Q3 24 | 3.9% | 0.3% | ||
| Q2 24 | 1.4% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.29× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 2.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LMB
| ODR | $99.8M | 72% |
| GCR | $39.0M | 28% |
